The U.S. is planning to invest $3.2 billion to develop antivirals to treat COVID-19 and other viruses that have the potential to become pandemics, moving to fill the gap in treatments for such serious illnesses as Ebola, dengue, West Nile and Middle East respiratory syndrome.